0%
Print report
Variant interpretation report

MSH6 c.4034_4042del, p.Val1345_Ala1347del

NM_000179.3:c.4034_4042del NP_000170.1:p.(Val1345_Ala1347del) In frame indel unknown · exon 10 View identifiers
Classification
Uncertain significance

Variant description:

The MSH6 NM_000179.3:c.4034_4042del (NP_000170.1:p.(Val1345_Ala1347del)) in-frame deletion variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About MSH6

MSH6 encodes a protein in the DNA mismatch repair system, which fixes errors made during DNA replication. Partnering with MSH2, it forms a complex that recognizes and helps correct mismatched DNA bases, keeping the genetic code stable. Inherited mutations in MSH6 cause Lynch syndrome (hereditary nonpolyposis colorectal cancer), raising the risk of colorectal, endometrial, ovarian, and other cancers, while mutations in both copies lead to constitutional mismatch repair deficiency. Because faulty mismatch repair drives tumor development and produces microsatellite instability, MSH6 acts as a tumor suppressor, and cancers with such repair defects often respond well to immune checkpoint inhibitor therapy.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen MSH6 VCEP v2.0. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 0
Pathogenic criteria applied · 1
PM2Supporting
PM2 · supporting

Met at Supporting: gnomAD v4.1 total AF is 2.48325e-06, below the PM2 threshold of <0.00002 (<1 in 50,000 alleles).

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: PM2 (supporting) was applied, but no pathogenic or benign combination rule was satisfied under the MSH6 VCEP framework.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

SpliceAI score
0.102 maximum delta

Recorded SpliceAI maximum delta score: 0.102. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied SpliceAI ↗
ClinVar submissions
4 reported laboratory submissions

4 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. MSH6, a DNA mismatch repair protein, is frequently mutated in colorectal, small bowel, and endometrial cancers.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen MSH6 VCEP v2.0, with the data and sources behind each one.

28 criteria with recorded statuses: 1 met · 2 not met · 9 not assessed · 16 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

For the three requested criteria, PVS1, PM4, and BP3 are not applicable under the governing MSH6 VCEP rules; no criterion is applied.

PS4, PP5, and BP6 are not applicable because the MSH6 VCEP explicitly marks each criterion Not Applicable.

PP4 and BP5 remain not assessed because the available evidence lacks the patient-specific tumor and phenotype observations required by their VCEP rules.

The three requested variant notations were searched in both declared VCEP reference files; no matching variant entry was found.

PP3, BP4, and BP7 are all not_applicable because the normalized variant is an in-frame exonic deletion and none of the three VCEP computational criteria covers that variant class or location.

Met · 1

PM2 SupportingVCEPMet at Supporting: gnomAD v4.1 total AF is 2.48325e-06, below the PM2 threshold of <0.00002 (<1 in 50,000 alleles). Details ▾Hide ▴
Reasoning

PM2 is met at Supporting strength. The governing MSH6 VCEP requires an absent or extremely rare allele frequency below 0.00002 (<1 in 50,000 alleles) in gnomAD v4.1. gnomAD v4.1 reports this variant at total AF 2.48325e-06 (4/1,610,792 alleles), with Grpmax FAF 7.9e-07 and 0 homozygotes; the total AF is below 0.00002.

VCEP rule
Absent/extremely rare allele frequency <0.00002 (<1 in 50,000 alleles ) in gnomAD v4 dataset
Evidence considered
  • gnomAD v4.1 variant 2-47806807-ACTGTAGATG-A (NM_000179.3:c.4034_4042del): total AF 2.48325e-06 from 4/1,610,792 alleles, 0 homozygotes, and Grpmax FAF 7.9e-07; total AF is below 0.00002.
  • The VCEP pilot spreadsheet, which declares PM2 precedent, was searched under c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching row was present.
Still missing
  • VCEP-pilot-variants---MMR.xlsx was searched for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching variant row was found.
Sources

Not met · 2 · evaluated, threshold not reached

BA1 VCEPNot met: gnomAD v4.1 Grpmax FAF is 7.9e-07, below the BA1 threshold of ≥0.0022 (0.22%). Details ▾Hide ▴
Reasoning

BA1 is not met. The governing MSH6 VCEP requires a gnomAD v4 Grpmax filtering allele frequency of at least 0.0022 (0.22%) and exclusion as a founder pathogenic variant. gnomAD v4.1 reports a Grpmax FAF of 7.9e-07 (0.000079%), with total AF 2.48325e-06 (4/1,610,792 alleles) and 0 homozygotes; the Grpmax FAF is below the threshold, so BA1 is not satisfied.

VCEP rule
GnomAD v4 Grpmax filtering allele frequency ≥ 0.0022 (0.22%) and variant is excluded as founder pathogenic variant.
Evidence considered
  • gnomAD v4.1 variant 2-47806807-ACTGTAGATG-A (NM_000179.3:c.4034_4042del): total AF 2.48325e-06 (4/1,610,792 alleles), 0 homozygotes, and Grpmax FAF 7.9e-07 (0.000079%), below the BA1 threshold.
  • The VCEP pilot spreadsheet was searched under c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching row was present.
Still missing
  • VCEP-pilot-variants---MMR.xlsx was searched for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching variant row was found.
Sources
BS1 VCEPNot met: gnomAD v4.1 Grpmax FAF is 7.9e-07, below the BS1 interval beginning at ≥0.00022 (0.022%). Details ▾Hide ▴
Reasoning

BS1 is not met. The governing MSH6 VCEP requires a gnomAD v4 Grpmax filtering allele frequency of at least 0.00022 and less than 0.0022 (0.022-0.22%), with exclusion as a founder pathogenic variant. gnomAD v4.1 reports a Grpmax FAF of 7.9e-07 (0.000079%), below the lower bound of the BS1 interval.

VCEP rule
GnomAD v4 Grpmax filtering allele frequency ≥ 0.00022 and < 0.0022 (0.022-0.22%) and variant is excluded as founder pathogenic variant.
Evidence considered
  • gnomAD v4.1 variant 2-47806807-ACTGTAGATG-A (NM_000179.3:c.4034_4042del): Grpmax FAF 7.9e-07 (0.000079%), below the BS1 lower bound of 0.00022; total AF 2.48325e-06 and 0 homozygotes.
  • The VCEP pilot spreadsheet was searched under c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching row was present.
Still missing
  • VCEP-pilot-variants---MMR.xlsx was searched for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching variant row was found.
Sources

Not assessed · 9 · no assessment recorded

PS2 VCEPNot assessed: no documented de novo result, parental testing, maternity/paternity confirmation, or VCEP de novo point assignment is available. Details ▾Hide ▴
Reasoning

The available case evidence contains no documented de novo observation, proband-parent testing result, maternity/paternity confirmation, or de novo point assignment. The VCEP provides point-based PS2 thresholds, but the required de novo evidence cannot be evaluated from the available records.

VCEP rule
VCEP PS2 is point-based: ≥ 4 de novo points = Very Strong; 2 - 3.5 de novo points = Strong; 1 - 1.5 de novo points = Moderate; 0.5 de novo points = Supporting.
Evidence considered
  • The case evidence records do not provide a proband-parent genotype comparison, confirmed de novo status, maternity/paternity confirmation, or de novo points for NM_000179.3:c.4031_4039del (normalized as c.4034_4042del).
  • The VCEP CSPEC defines PS2 using de novo point ranges, but no case-specific point value is available to apply those thresholds.
Still missing
  • Documented proband variant status and parental testing results are needed.
  • Maternity/paternity confirmation and any VCEP de novo point assignment are needed.
Sources
PS3 VCEPNot assessed: no variant-specific functional assay result or calibrated functional odds were identified for the in-frame p.Val1345_Ala1347del deletion. Details ▾Hide ▴
Reasoning

The MSH6 VCEP PS3 rule permits pathogenic functional evidence from calibrated assays or an MMR function defect assessed through the MMR functional assay flowchart. This variant is an in-frame deletion, so the flowchart pathway is applicable, but the case evidence contains no variant-specific functional assay result, calibrated functional odds, MMR repair readout, protein-function result, or RNA result for NM_000179.3:c.4034_4042del (p.Val1345_Ala1347del; p.V1345_A1347del). The governing Functional-assay-SVI-documentation-MMR.xlsx was searched for all three variant notations and contains no matching entry; its calibrated assay rows document assay methodology and controls, not a result for this variant. Therefore PS3 cannot be assigned.

VCEP rule
MMR function defect following functional assay flowchart*
Evidence considered
  • The MSH6 VCEP PS3 specification states: calibrated functional assays with functional odds forpathogenicity > 18.7; calibrated functional assays with functional odds for pathogenicity >4.3 and <= 18.7, or MMR function defect following the functional assay flowchart, support PS3 at lower strengths; calibrated functional odds >2.08 and <= 4.3 support PS3 at Supporting strength.
  • Functional-assay-flowchart.pdf, page 1: an in-frame indel follows the branch asking whether a calibrated functional assay was conducted; without a calibrated assay, two independent concordant assays are required, with deficient function reached through concordant deficient repair/protein/localization or cellular MMR findings.
  • Functional-assay-SVI-documentation-MMR.xlsx, sheet 'MMR assays': the curated table lists validated assay methods, controls, and proposed PS3/BS3 strengths, including the Drost MSH6 functional-assay publications PMID:30504929 and PMID:31965077, but no row for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del.
  • The case evidence identifies the normalized variant as NM_000179.3:c.4034_4042del, NP_000170.1:p.(Val1345_Ala1347del), and NP_000170.1:p.(V1345_A1347del), with no variant-specific functional assay result.
Still missing
  • Functional-assay-SVI-documentation-MMR.xlsx was searched for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching variant entry was found.
  • Functional-assay-flowchart.pdf provides the applicable in-frame-indel decision pathway, but no variant-specific assay outcome is available to reach deficient function or calibrated functional odds.
  • No variant-specific protein, MMR repair, or RNA functional result is present in the case evidence bundle.
Sources
PM3 VCEPNot assessed: no affected-proband observation with a pathogenic MSH6 variant in confirmed trans phase and no VCEP PM3 point total are documented. Details ▾Hide ▴
Reasoning

The VCEP PM3 criterion is points-based, but the available case evidence does not document any affected proband carrying this variant with a known pathogenic MSH6 variant, confirmed trans or cis phase, parental or offspring phase testing, or a PM3 point assignment. Therefore, PM3 cannot be evaluated without substituting non-VCEP assumptions.

VCEP rule
PM3 is assigned according to the VCEP's point thresholds.
Evidence considered
  • The case evidence contains no documented affected proband with a known pathogenic MSH6 variant in trans or cis with NM_000179.3:c.4031_4039del (normalized as NM_000179.3:c.4034_4042del).
  • No parental or offspring testing results confirming phase and no PM3 point assignment are provided.
Still missing
  • Affected-proband observations involving this variant and a known pathogenic MSH6 variant are not documented.
  • Phase with any second MSH6 variant is not documented; parental or offspring testing results are unavailable.
  • No VCEP PM3 point assignment can be derived from the available evidence.
Sources
PP1 VCEPNot assessed: no pedigree segregation data, informative meioses, or combined Bayes Likelihood Ratio is available for comparison with the VCEP thresholds. Details ▾Hide ▴
Reasoning

The available case evidence contains no pedigree, affected-relative genotypes, unaffected-relative genotypes, meioses, segregation observations, or combined Bayes Likelihood Ratio. The VCEP PP1 thresholds therefore cannot be evaluated.

VCEP rule
Co-segregation with disease in pedigree(s) with a combined* Bayes Likelihood Ratio >18.7 in ≥2 families; >4.3 & ≤18.7; or >2.08 & ≤4.3.
Evidence considered
  • The case evidence provides no disease-segregation pedigree, relative genotype results, number of informative meioses, or combined Bayes Likelihood Ratio for this variant.
  • The VCEP PP1 specification requires a combined Bayes Likelihood Ratio to distinguish Supporting (>2.08 and ≤4.3), Moderate (>4.3 and ≤18.7), and Strong (>18.7) evidence.
Still missing
  • Pedigree and phenotype information for informative relatives are needed.
  • Variant genotypes for affected and unaffected relatives and a VCEP-compatible combined Bayes Likelihood Ratio are needed.
Sources
PP4 VCEPNot assessed: no patient-specific MSI, tumor-genome, or MMR-protein-expression result is available to compare with the VCEP's PP4 tumor thresholds. Details ▾Hide ▴
Reasoning

The VCEP permits PP4 at Supporting strength for 1 CRC or endometrial MSI-H tumor using a standard panel of 5-10 markers or tumor genome and/or loss of MMR protein expression consistent with the variant location; Moderate requires 2 independent qualifying tumors, and Strong requires at least 3 independent qualifying tumors in at least 2 families. The available case evidence does not provide patient-specific tumor MSI, tumor-genome, or MMR-protein-expression findings, so the criterion cannot be assessed. Searches of Table-for-CMMRD-diagnosis.pdf.txt and VCEP-pilot-variants---MMR.xlsx.txt found no entry for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del.

VCEP rule
1 CRC/Endometrial MSI-H tumor using a standard panel of 5-10 markers<sup>e</sup> or tumor genome and/or loss of MMR protein expression consistent with the variant location. MSI-H tumor with inconsistent protein expression does not meet PP4. ... 2 independent CRC/Endometrial MSI-H tumors using a standard panel of 5-10 markers<sup>e</sup> or tumor genome and/or loss of MMR protein expression consistent with the variant location. MSI-H tumor with inconsistent protein expression does not meet PP4_Moderate. ... ≥3 independent CRC/Endometrial MSI-H tumors in ≥2 families using a standard panel of 5-10 markers<sup>e</sup> or tumor genome and/or loss of MMR protein expression consistent with the variant location. MSI-H tumor with inconsistent protein expression does not meet PP4_Strong.
Evidence considered
  • MSH6 VCEP PP4 rule: Supporting requires 1 CRC/endometrial MSI-H tumor using a standard panel of 5-10 markers or tumor genome and/or loss of MMR protein expression consistent with the variant location; Moderate requires 2 independent tumors; Strong requires at least 3 independent tumors in at least 2 families.
  • Table-for-CMMRD-diagnosis.pdf.txt was searched under c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del with no matching entry.
  • VCEP-pilot-variants---MMR.xlsx.txt was searched under c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del with no matching entry.
Still missing
  • Patient-specific tumor MSI status and testing method are unavailable.
  • Patient-specific MMR protein expression and whether it is consistent with the variant location are unavailable.
  • No matching variant entry was found when searching Table-for-CMMRD-diagnosis.pdf.txt.
  • No matching variant entry was found when searching VCEP-pilot-variants---MMR.xlsx.txt.
Sources
BS2 VCEPNot assessed: no qualifying in-trans co-occurrence, phase confirmation, cancer-age condition, or CMMRD-status documentation is available. Details ▾Hide ▴
Reasoning

BS2 cannot be assessed from the available evidence. The VCEP requires documented co-occurrence in trans with a known pathogenic sequence variant in MSH6 in a patient with colorectal cancer after age 45, or another Lynch-syndrome cancer above its median age of onset, no previous or current clinical manifestations of CMMRD, and phase confirmation through parental or offspring testing. The case evidence contains no qualifying co-occurrence, phase, cancer-age, or CMMRD-status documentation.

VCEP rule
Co-occurrence _​in trans_ with a known pathogenic sequence variant in the same gene in a patient with colorectal cancer after age 45 (or other LS cancer above the median age of onset for that cancer in LS<sup>​d​</sup>), and who has no previous or current evidence of clinical manifestations of CMMRD as per Aronson et al 2022 (Refer to 'Table for CMMRD diagnosis.pdf'). Confirmation of phase requires testing of parents or offspring.
Evidence considered
  • The case evidence documents population observations for the variant but does not document a patient with this variant in trans with a known pathogenic MSH6 sequence variant, confirmed phase, the required cancer-age condition, and absence of CMMRD manifestations.
  • The VCEP pilot spreadsheet was searched under c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching row was present.
Still missing
  • No qualifying in-trans co-occurrence record, phase testing, cancer-age documentation, or CMMRD-status evidence was identified in the case evidence.
  • VCEP-pilot-variants---MMR.xlsx was searched for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching variant row was found.
Sources
BS3 VCEPNot assessed: no variant-specific proficient-function result or calibrated functional odds were identified for the in-frame p.Val1345_A1347del deletion. Details ▾Hide ▴
Reasoning

The MSH6 VCEP BS3 rule requires calibrated functional evidence showing low functional odds for pathogenicity or variant-specific proficient function in protein and mRNA-based assays under the MMR functional assay flowchart. This variant is an in-frame deletion and the applicable flowchart pathway is available, but no variant-specific benign/proficient functional result, calibrated functional odds, or qualifying RNA assay result is present. Functional-assay-SVI-documentation-MMR.xlsx was searched for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del, with no matching entry. Therefore BS3 cannot be assigned.

VCEP rule
Variant-specific proficient function in protein and mRNA-based lab assays as per MMR functional assay flowchart.
Evidence considered
  • The MSH6 VCEP BS3 specification states: calibrated functional assays with functional odds for Pathogenicity <= 0.05, or synonymous/intronic variants with no associated mRNA aberration, support BS3 at Strong strength; calibrated functional assays with functional odds >0.05 and <=0.48, or variant-specific proficient function in protein and mRNA-based lab assays as per the MMR functional assay flowchart, support BS3 at Supporting strength.
  • Functional-assay-flowchart.pdf, page 1: for an in-frame indel without a calibrated assay, proficient function requires concordant assay findings consistent with wild-type function, including nuclear localization, sensitivity to DNA damage, and no mutator phenotype after the specified assay sequence.
  • Functional-assay-SVI-documentation-MMR.xlsx, sheet 'MMR assays': the curated assay table lists assay controls and proposed BS3 strengths, including the Drost MSH6 functional-assay publications PMID:30504929 and PMID:31965077, but no row for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del.
  • The case evidence identifies the normalized variant as NM_000179.3:c.4034_4042del, NP_000170.1:p.(Val1345_Ala1347del), and NP_000170.1:p.(V1345_A1347del), with no variant-specific proficient-function assay result.
Still missing
  • Functional-assay-SVI-documentation-MMR.xlsx was searched for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching variant entry was found.
  • Functional-assay-flowchart.pdf provides the applicable in-frame-indel pathway, but no variant-specific proficient-function result is available.
  • No calibrated functional odds or variant-specific protein and mRNA assay result meeting the BS3 rule is present in the case evidence bundle.
Sources
BS4 VCEPNot assessed: no non-segregating carriers, informative pedigree, or combined Bayes Likelihood Ratio is available for comparison with the VCEP thresholds. Details ▾Hide ▴
Reasoning

The available case evidence contains no documented non-segregation, unaffected carriers, informative pedigree, or combined Bayes Likelihood Ratio. The VCEP BS4 thresholds therefore cannot be evaluated.

VCEP rule
Lack of co-segregation with disease in pedigree(s) with a combined* Bayes Likelihood Ratio <0.05 (Strong) or >0.05 & ≤0.48 (Supporting).
Evidence considered
  • The case evidence provides no unaffected carrier genotype, non-segregation observation, pedigree data, or combined Bayes Likelihood Ratio for this variant.
  • The VCEP BS4 specification requires a combined Bayes Likelihood Ratio <0.05 for Strong or >0.05 and ≤0.48 for Supporting evidence.
Still missing
  • Documented unaffected carriers or other non-segregation observations are needed.
  • A VCEP-compatible combined Bayes Likelihood Ratio is needed.
Sources
BP5 VCEPNot assessed: no patient-specific tumor count or MSS, MMR-protein, BRAF V600E, or MLH1-methylation result is available for the BP5 requirements. Details ▾Hide ▴
Reasoning

The MSH6 VCEP BP5 rule requires either 2 or 3 qualifying tumors for Supporting or at least 4 qualifying tumors for Strong: CRC/endometrial tumors with MSS and/or no loss of MMR protein expression, or LS-spectrum tumors with MMR-protein loss inconsistent with the gene containing the variant; an alternative requires BRAF V600E or MLH1 methylation findings. The available case evidence contains no patient-specific tumor counts, MSI/MSS results, MMR-protein-expression results, BRAF V600E result, or MLH1-methylation result, so BP5 cannot be assessed.

VCEP rule
≥ 4 tumors: CRC/Endometrial tumors with MSS and/or no loss of MMR protein expression and/or LS spectrum tumors<sup>d</sup> with loss of MMR protein(s) that is inconsistent with the gene demonstrating genetic variation ... OR ... ≥2 BRAF V600E (CRC only)/MLH1 methylation (in LS spectrum tumor only) with MSI-H/MLH1 loss. ... 2 or 3 tumors: CRC/Endometrial tumors with MSS and/or no loss of MMR protein expression and/or LS spectrum tumors<sup>d</sup> with loss of MMR protein(s) that is inconsistent with the gene demonstrating genetic variation. ... OR ... 1 BRAF V600E (Colon only)/MLH1 methylation (in LS spectrum tumor only) with MSI-H/MLH1 loss.
Evidence considered
  • MSH6 VCEP BP5 Supporting rule requires 2 or 3 qualifying tumors or 1 BRAF V600E/MLH1-methylation finding.
  • MSH6 VCEP BP5 Strong rule requires at least 4 qualifying tumors or at least 2 BRAF V600E/MLH1-methylation findings.
Still missing
  • Patient-specific qualifying tumor count and tumor types are unavailable.
  • Patient-specific MSS/MSI and MMR-protein-expression findings are unavailable.
  • Patient-specific BRAF V600E and MLH1-methylation findings are unavailable.
Sources
Not applicable · 16· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: the variant is an in-frame 9-bp exon 10 deletion, whereas the VCEP PVS1 rule names nonsense, frameshift, splice, large-alteration, or RNA-confirmed aberration paths. Details ▾Hide ▴
Reasoning

The governing MSH6 VCEP PVS1 rule applies to nonsense/frameshift variants introducing a premature termination codon, large genomic alterations, qualifying canonical splice variants, or specified patient-RNA-confirmed splicing aberrations. This variant is NM_000179.3:c.4034_4042del (equivalent to the submitted c.4031_4039del), an in-frame 9-bp deletion producing p.(Val1345_Ala1347del) in exon 10, not a nonsense, frameshift, canonical splice, large genomic alteration, or documented RNA-confirmed splicing aberration. The PVS1 decision-tree file likewise contains no applicable in-frame small-deletion path. No exact entry was found after searching PVS1_DecisionTree_MMR.pdf.txt and VCEP-pilot-variants---MMR.xlsx.txt for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del.

VCEP rule
Nonsense/frameshift variant introducing Premature Termination Codon (PTC)<sup>a</sup> ≤ codon 1341 in _MSH6_. Refer to Appendix for details.
Evidence considered
  • CSPEC MSH6 v2.0 PVS1 rule: the very-strong path names a nonsense/frameshift variant introducing a premature termination codon at or before codon 1341, along with separate large-alteration, canonical-splice, and patient-RNA-confirmed splicing paths.
  • Case variant facts: NM_000179.3:c.4034_4042del / NP_000170.1:p.(Val1345_Ala1347del), exon 10, consequence class in_frame_indel_unknown, canonical splice consensus false.
  • PVS1_DecisionTree_MMR.pdf.txt was searched for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching variant entry was found.
  • VCEP-pilot-variants---MMR.xlsx.txt was searched for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching variant entry was found.
Still missing
  • No exact variant entry found in PVS1_DecisionTree_MMR.pdf.txt after searching c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del.
  • No exact variant entry found in VCEP-pilot-variants---MMR.xlsx.txt after searching c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del.
Sources
PS1 N/ANot applicable: the variant is an in-frame three-residue deletion, whereas PS1 requires a predicted missense substitution or the same non-canonical splice nucleotide. Details ▾Hide ▴
Reasoning

The normalized variant is an in-frame deletion, NM_000179.3:c.4034_4042del, p.(Val1345_Ala1347del), not a predicted missense substitution or a variant affecting a non-canonical splice nucleotide. Therefore neither PS1 route in the MSH6 VCEP applies. The required VCEP variant searches found no entry for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del in MMR-Functional-domains.pdf.txt; that file is a domain schematic rather than a same-amino-acid pathogenic-variant table.

VCEP rule
A predicted missense substitution that encodes the same amino acid change with a different underlying nucleotide change previously established by this VCEP as Pathogenic (not a predicted or confirmed splice defect).
Evidence considered
  • Case normalization: NM_000179.3:c.4034_4042del; NP_000170.1:p.(Val1345_Ala1347del), classified as an in-frame deletion.
  • MMR-Functional-domains.pdf.txt was searched for c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del; no matching variant entry was found.
Still missing
  • No entry for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del was found in MMR-Functional-domains.pdf.txt; this file does not provide PS1 comparator classifications.
Sources
PS4 VCEPNot applicable: the MSH6 VCEP explicitly designates PS4 as Not Applicable, regardless of the available literature or case-control evidence. Details ▾Hide ▴
Reasoning

The MSH6 VCEP specification explicitly marks PS4 as Not Applicable. Therefore, no case-control calculation or phenotype evidence can activate PS4 under this governing framework. The literature packet's ai_classified_papers list is empty; the reviewed extracted papers do not mention this variant, and no VCEP-file entry was found for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del.

VCEP rule
Not Applicable
Evidence considered
  • MSH6 CSPEC criterion entry for PS4: applicability is "Not Applicable".
  • The literature_pass.json packet has ai_classified_papers: [].
Still missing
  • No matching variant entry was found when searching Table-for-CMMRD-diagnosis.pdf.txt.
  • No matching variant entry was found when searching VCEP-pilot-variants---MMR.xlsx.txt.
Sources
PM1 VCEPNot applicable: the MSH6 VCEP explicitly excludes PM1 because no recognized hotspot or domain-based PM1 route is approved for classification. Details ▾Hide ▴
Reasoning

The MSH6 VCEP explicitly marks PM1 not applicable and states that no recognized mutational hotspots can be used for classification; it also states that pathogenic variants are generalized across the MMR functional domains. The authoritative vcep_materials.json domain_tables entry for MSH6 is empty, and the governing MMR-Functional-domains.pdf.txt schematic lists the MSH6 ATPase domain at residues 1132-1360 and MSH2 interaction domain at residues 1302-1360, but those regions cannot override the VCEP's explicit PM1 inapplicability.

VCEP rule
There are no recognized mutational hot spots that could be used for classification purposes. While there are functional domains in the MMR genes, the distribution of pathogenic variants is generalized over all the domains (unpublished data).
Evidence considered
  • MSH6 VCEP PM1 specification: PM1 is not applicable; it states there are no recognized mutational hotspots and that pathogenic-variant distribution is generalized over MMR functional domains.
  • MMR-Functional-domains.pdf.txt lists MSH6 ATPase residues 1132-1360 and MSH2 interaction residues 1302-1360; the domain schematic was searched under all three supplied variant notations without a variant-specific entry.
  • vcep_materials.json has domain_tables = {} for MSH6.
Still missing
  • No entry for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del was found in MMR-Functional-domains.pdf.txt.
Sources
PM4 VCEPNot applicable: the MSH6 VCEP explicitly designates PM4 as Not Applicable for this framework. Details ▾Hide ▴
Reasoning

The MSH6 CSPEC explicitly marks PM4 as Not Applicable. Therefore the in-frame deletion is not assessed under PM4, regardless of its protein-length change.

VCEP rule
Not Applicable
Evidence considered
  • MSH6 CSPEC v2.0 criterion entry for PM4: applicability is Not Applicable.
Sources
PM5 N/ANot applicable: the target is an in-frame deletion, while PM5 requires a missense change and a different pathogenic or likely pathogenic missense change at the same residue. Details ▾Hide ▴
Reasoning

The target is an in-frame deletion, not a missense change. The MSH6 VCEP PM5 rule is restricted to a missense change at an amino-acid residue and requires a different VCEP-classified pathogenic or likely pathogenic missense change at that residue, with PP3 supporting for the target. Therefore PM5 is not applicable. The PM5 candidate file also records the consequence class as in_frame_indel_unknown and no same-residue candidates.

VCEP rule
Missense change at an amino acid residue where a different missense change was classified by this VCEP as Pathogenic on the protein level and not due to aberrant splicing. Only use PM5 if PP3 is supporting for the missense change. Use PM5\_Supporting if other variant is Likely Pathogenic due to a missense alteration.
Evidence considered
  • The target consequence is in_frame_indel_unknown, with protein consequence p.(Val1345_Ala1347del), not a missense substitution.
  • pm5_candidates.json reports eligible_for_classic_pm5_search = false, total_candidates_seen = 0, and same_residue_candidates = 0 because the target is not missense.
Still missing
  • No entry for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del was found in MMR-Functional-domains.pdf.txt.
Sources
cspec ↗pm5_candidates
PM6 VCEPNot applicable: the MSH6 VCEP specification explicitly marks PM6 as Not Applicable. Details ▾Hide ▴
Reasoning

The ClinGen InSiGHT MSH6 VCEP specification explicitly marks PM6 as Not Applicable; therefore no alternative PM6 rule is evaluated.

VCEP rule
Not Applicable
Evidence considered
  • The MSH6 Version 2.0 CSPEC entry for PM6 states: Not Applicable.
Sources
PP2 VCEPNot applicable: the MSH6 VCEP explicitly states that the low rate of benign missense variation PP2 rule does not apply. Details ▾Hide ▴
Reasoning

The MSH6 VCEP explicitly marks PP2 not applicable and states that the low-benign-missense-rate rule does not apply. No generic gene-level missense mechanism rule is substituted.

VCEP rule
Missense variant in a gene with low rate of benign missense changes does not apply.
Evidence considered
  • The MSH6 VCEP PP2 entry is marked Not applicable and says: Missense variant in a gene with low rate of benign missense changes does not apply.
Sources
PP3 N/ANot applicable: the variant is an in-frame deletion, outside PP3's missense or non-canonical splice-nucleotide scope, regardless of the available SpliceAI score. Details ▾Hide ▴
Reasoning

The normalized variant is an in-frame deletion, NM_000179.3:c.4034_4042del (p.(Val1345_Ala1347del)), not a missense variant or a variant at a non-canonical splice nucleotide. The VCEP PP3 rule is limited to missense HCI-prior evidence or predicted splice defects at non-canonical splicing nucleotides using SpliceAI; therefore the available SpliceAI score is outside PP3's governing scope and cannot be used. The exact variant was searched in HCI-PRIORS-MSH6.txt.txt under c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del, with no entry found.

VCEP rule
Missense variant with HCI prior probability for pathogenicity >0.81 as per [https://hci-priors.hci.utah.edu/PRIORS](https://hci-priors.hci.utah.edu/PRIORS) ... Missense variant with HCI prior probability for pathogenicity >0.68 & <=0.81 as per [https://hci-priors.hci.utah.edu/PRIORS](https://hci-priors.hci.utah.edu/PRIORS)  OR Predicted splice defect for non-canonical splicing nucleotides using SpliceAI with delta score >= 0.2 as per Walker et al 2023.
Evidence considered
  • Normalized variant: NM_000179.3:c.4034_4042del, NP_000170.1:p.(Val1345_Ala1347del), an in-frame deletion in exon 10.
  • The available SpliceAI result has max delta score 0.102, but PP3 names SpliceAI only for predicted splice defects at non-canonical splicing nucleotides; this exon in-frame deletion is outside that rule path.
Still missing
  • No exact entry for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/MSH6/fulltext/HCI-PRIORS-MSH6.txt.txt; this HCI table is restricted to missense substitutions and is not applicable to this in-frame deletion.
Sources
PP5 VCEPNot applicable: the MSH6 VCEP explicitly designates PP5 as Not Applicable, and no variant-specific paper evidence overrides that rule. Details ▾Hide ▴
Reasoning

The MSH6 VCEP specification explicitly marks PP5 as Not Applicable. The reviewed ClinVar-linked papers either do not mention this variant or provide no variant-specific evidence, and no VCEP-file entry was found for the three requested variant notations.

VCEP rule
Not Applicable
Evidence considered
  • MSH6 CSPEC criterion entry for PP5: applicability is "Not Applicable".
  • Paper extracts for PMID:23788249, PMID:26467025, and PMID:34012068 report no mention of the variant and no variant-specific evidence.
Still missing
  • No matching variant entry was found when searching Table-for-CMMRD-diagnosis.pdf.txt.
  • No matching variant entry was found when searching VCEP-pilot-variants---MMR.xlsx.txt.
Sources
BP1 VCEPNot applicable: the MSH6 VCEP excludes BP1, and the target is an in-frame deletion rather than a missense variant. Details ▾Hide ▴
Reasoning

The MSH6 VCEP explicitly marks BP1 not applicable and states that missense variation in a gene where only loss of function causes disease is not applicable. The target is also an in-frame deletion rather than a missense variant, so BP1 cannot be applied.

VCEP rule
Missense variant in a gene where only loss of function causes disease is not applicable.
Evidence considered
  • The MSH6 VCEP BP1 entry is marked Not applicable and says: Missense variant in a gene where only loss of function causes disease is not applicable.
Sources
BP2 VCEPNot applicable: the MSH6 VCEP specification explicitly marks BP2 as not applicable. Details ▾Hide ▴
Reasoning

The ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis VCEP MSH6 Version 2.0 specification explicitly marks BP2 as not applicable; no BP2 evidence assessment is permitted under this governing framework.

VCEP rule
Not Applicable
Evidence considered
  • The VCEP CSPEC entry for BP2 has applicability set to Not Applicable.
Sources
BP3 VCEPNot applicable: the MSH6 VCEP explicitly designates BP3 as Not Applicable for this framework. Details ▾Hide ▴
Reasoning

The MSH6 CSPEC explicitly marks BP3 as Not Applicable. No repeat-region or other BP3 assessment can override that VCEP applicability decision.

VCEP rule
Not Applicable
Evidence considered
  • MSH6 CSPEC v2.0 criterion entry for BP3: applicability is Not Applicable.
Sources
BP4 N/ANot applicable: the variant is an in-frame deletion, outside BP4's missense or intronic/synonymous scope, so SpliceAI 0.102 cannot establish BP4. Details ▾Hide ▴
Reasoning

The normalized variant is an in-frame deletion, not a missense, intronic, or synonymous variant. The VCEP BP4 rule applies either to missense variants with an HCI prior probability below 0.11 or to intronic/synonymous variants with SpliceAI delta score <=0.1; neither path covers this in-frame deletion. Consequently, the available SpliceAI score of 0.102 is not evidence for BP4. The exact variant was searched in HCI-PRIORS-MSH6.txt.txt under c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del, with no entry found.

VCEP rule
Missense variant with HCI-prior probability of pathogenicity \<0.11 as per https://hci-priors.hci.utah.edu/PRIORS ... For intronic and synonymous variants: SpliceAI predicts no splicing impact with delta score \<= 0.1 as per Walker et al 2023.
Evidence considered
  • Normalized variant: NM_000179.3:c.4034_4042del, NP_000170.1:p.(Val1345_Ala1347del), an in-frame deletion in exon 10.
  • SpliceAI max delta score is 0.102, but the VCEP BP4 SpliceAI path is restricted to intronic and synonymous variants.
Still missing
  • No exact entry for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/MSH6/fulltext/HCI-PRIORS-MSH6.txt.txt; this HCI table is restricted to missense substitutions and is not applicable to this in-frame deletion.
Sources
BP6 VCEPNot applicable: the MSH6 VCEP explicitly designates BP6 as Not Applicable under its version 2.0 specification. Details ▾Hide ▴
Reasoning

The MSH6 VCEP specification explicitly marks BP6 as Not Applicable. Therefore, no benign assertion from a non-expert source can activate BP6 under this governing framework.

VCEP rule
Not Applicable
Evidence considered
  • MSH6 CSPEC criterion entry for BP6: applicability is "Not Applicable".
Sources
BP7 N/ANot applicable: the variant is an exonic in-frame deletion, not a synonymous or intronic variant at or beyond the BP7 -21/+7 boundary. Details ▾Hide ▴
Reasoning

The normalized variant is an in-frame exonic deletion, not a synonymous or intronic variant at or beyond -21/+7 of an exon. It is therefore outside the VCEP BP7 applicability scope, and no predictor score is relevant to BP7.

VCEP rule
A synonymous (silent) or intronic variant at or beyond -21/+7 (5′/3′ exonic). Variants may satisfy both BP7 and BP4.
Evidence considered
  • Normalized variant: NM_000179.3:c.4034_4042del, NP_000170.1:p.(Val1345_Ala1347del), an in-frame exonic deletion.
Sources

Identifiers

Gene
MSH6
Transcript
NM_000179.3
Coding (HGVS c.)
NM_000179.3:c.4034_4042del
Protein (HGVS p.)
NP_000170.1:p.(Val1345_Ala1347del)
GRCh38
chr2:47806807 ACTGTAGATG>A
GRCh37
chr2:48033946 ACTGTAGATG>A
Location and type
Exon 10 · in frame indel unknown
ClinVar
220947

Gene diagram

Every interpreted variant in MSH6, mapped onto the exon structure of NM_000179.3. Select a row to find it on the plot.

MSH6NM_000179.3
Fetching transcript structure from UCSC…
gnomAD v4.1 4 / 1,610,792 alleles AF 2.48e-06 · 0 homozygotes · FAF 7.9e-07
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 2.5e-06 · 4 / 1,610,792 alleles · 0 hom · FAF 7.9e-07
European (non-Finnish)4 / 1,178,706 3.4e-06
0 alternate alleles recorded in 9 other groups: Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 2.48325e-06; MAF= 0.00025%, 4/1610792 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 3.39355e-06; MAF= 0.00034%, 4/1178706 alleles, homozygotes = 0); grpmax FAF= 7.9e-07.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat -28 bp
0.070
SpliceAI acceptor gainat -23 bp
0.014
SpliceAI donor lossat -156 bp
0.102
SpliceAI donor gainat +93 bp
0.007
Pangolin splice lossmagnitude shown
-0.110
Pangolin splice gain
0.004

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

PP3 N/ANot applicable: the variant is an in-frame deletion, outside PP3's missense or non-canonical splice-nucleotide scope, regardless of the available SpliceAI score. Details ▾Hide ▴
Reasoning

The normalized variant is an in-frame deletion, NM_000179.3:c.4034_4042del (p.(Val1345_Ala1347del)), not a missense variant or a variant at a non-canonical splice nucleotide. The VCEP PP3 rule is limited to missense HCI-prior evidence or predicted splice defects at non-canonical splicing nucleotides using SpliceAI; therefore the available SpliceAI score is outside PP3's governing scope and cannot be used. The exact variant was searched in HCI-PRIORS-MSH6.txt.txt under c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del, with no entry found.

VCEP rule
Missense variant with HCI prior probability for pathogenicity >0.81 as per [https://hci-priors.hci.utah.edu/PRIORS](https://hci-priors.hci.utah.edu/PRIORS) ... Missense variant with HCI prior probability for pathogenicity >0.68 & <=0.81 as per [https://hci-priors.hci.utah.edu/PRIORS](https://hci-priors.hci.utah.edu/PRIORS)  OR Predicted splice defect for non-canonical splicing nucleotides using SpliceAI with delta score >= 0.2 as per Walker et al 2023.
Evidence considered
  • Normalized variant: NM_000179.3:c.4034_4042del, NP_000170.1:p.(Val1345_Ala1347del), an in-frame deletion in exon 10.
  • The available SpliceAI result has max delta score 0.102, but PP3 names SpliceAI only for predicted splice defects at non-canonical splicing nucleotides; this exon in-frame deletion is outside that rule path.
Still missing
  • No exact entry for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/MSH6/fulltext/HCI-PRIORS-MSH6.txt.txt; this HCI table is restricted to missense substitutions and is not applicable to this in-frame deletion.
Sources
BP4 N/ANot applicable: the variant is an in-frame deletion, outside BP4's missense or intronic/synonymous scope, so SpliceAI 0.102 cannot establish BP4. Details ▾Hide ▴
Reasoning

The normalized variant is an in-frame deletion, not a missense, intronic, or synonymous variant. The VCEP BP4 rule applies either to missense variants with an HCI prior probability below 0.11 or to intronic/synonymous variants with SpliceAI delta score <=0.1; neither path covers this in-frame deletion. Consequently, the available SpliceAI score of 0.102 is not evidence for BP4. The exact variant was searched in HCI-PRIORS-MSH6.txt.txt under c.4034_4042del, p.Val1345_Ala1347del, and p.V1345_A1347del, with no entry found.

VCEP rule
Missense variant with HCI-prior probability of pathogenicity \<0.11 as per https://hci-priors.hci.utah.edu/PRIORS ... For intronic and synonymous variants: SpliceAI predicts no splicing impact with delta score \<= 0.1 as per Walker et al 2023.
Evidence considered
  • Normalized variant: NM_000179.3:c.4034_4042del, NP_000170.1:p.(Val1345_Ala1347del), an in-frame deletion in exon 10.
  • SpliceAI max delta score is 0.102, but the VCEP BP4 SpliceAI path is restricted to intronic and synonymous variants.
Still missing
  • No exact entry for c.4034_4042del, p.Val1345_Ala1347del, or p.V1345_A1347del was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/MSH6/fulltext/HCI-PRIORS-MSH6.txt.txt; this HCI table is restricted to missense substitutions and is not applicable to this in-frame deletion.
Sources
BP7 N/ANot applicable: the variant is an exonic in-frame deletion, not a synonymous or intronic variant at or beyond the BP7 -21/+7 boundary. Details ▾Hide ▴
Reasoning

The normalized variant is an in-frame exonic deletion, not a synonymous or intronic variant at or beyond -21/+7 of an exon. It is therefore outside the VCEP BP7 applicability scope, and no predictor score is relevant to BP7.

VCEP rule
A synonymous (silent) or intronic variant at or beyond -21/+7 (5′/3′ exonic). Variants may satisfy both BP7 and BP4.
Evidence considered
  • Normalized variant: NM_000179.3:c.4034_4042del, NP_000170.1:p.(Val1345_Ala1347del), an in-frame exonic deletion.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.10).

8 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders.
    The supplied paper does not explicitly mention MSH6 or the variant c.4034_4042del / NP_000170.1:p.(V1345_A1347del). No variant-specific functional assay, patient observation, segregation result, population-frequency finding, or gene-specific mechanism is reported for this variant.
    Does not name this variant
    PMID 26467025 ↗
    Quoted passage
    Over 16,500 pathogenicity assessments on 11,894 distinct variants in 338 genes causing neurological, endocrine, and nephrotic genetic disorders were performed on the sequencing data.

    Materials and Methods, Data Collection and Storage

  • ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
    Green RC et al. · 2013
    This paper does not mention MSH6, c.4034_4042del, or p.(V1345_A1347del), and provides no variant-specific functional, clinical, segregation, or population-frequency evidence. It presents general ACMG recommendations for reporting selected incidental findings from clinical exome and genome sequencing.
    Does not name this variant
    PMID 23788249 ↗
  • ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing.
    ACMG Board of Directors · 2015
    No paper-specific finding is recorded.
    PMID 25356965 ↗
  • Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
    Kalia SS et al. · 2017
    No paper-specific finding is recorded.
    PMID 27854360 ↗
  • ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT et al. · 2021
    This paper does not report the MSH6 c.4034_4042del variant or provide MSH6-specific functional, clinical, segregation, or population-frequency evidence. It is an ACMG policy and gene-list review paper rather than a variant-level cohort or assay report.
    Does not name this variant
    PMID 34012068 ↗
    Quoted passage
    Other technical difficulties were noted for genes such as EPCAM associated with Lynch syndrome and GREM1-associated polyposis, where routine detection of common deletions or duplications could be difficult at this time by ES/GS in many laboratories.

    Considerations for Specific Phenotype Categories, Genes related to cancer phenotypes, Not recommended for addition to the SF v3.0 list

  • The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.
    de Oliveira JM et al. · 2022
    No paper-specific finding is recorded.
    PMID 35534704 ↗
  • ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT et al. · 2022
    No paper-specific finding is recorded.
    PMID 35802134 ↗
  • Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
    Nykamp K et al. · 2017
    No paper-specific finding is recorded.
    PMID 28492532 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 2.48325e-06; MAF= 0.00025%, 4/1610792 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 3.39355e-06; MAF= 0.00034%, 4/1178706 alleles, homozygotes = 0); grpmax FAF= 7.9e-07.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Uncertain significance (4 clinical laboratories). (ClinVarID = 220947)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.10).

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. MSH6, a DNA mismatch repair protein, is frequently mutated in colorectal, small bowel, and endometrial cancers.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.